#USA #Cranford #CTCL #LYMPHIR #Citius Oncology

Citius Oncology Reports Financial Results and Business Updates for Q2 2026

Citius Oncology, Inc., the oncology-focused subsidiary of Citius Pharmaceuticals, recently reported its financial results for the second quarter of fiscal 2026, alongside crucial business updates related to their flagship product, LYMPHIR.

Financial Performance Overview

For the first half of fiscal 2026, Citius Oncology reported a remarkable net revenue of $5.6 million, primarily attributed to the commercial launch of LYMPHIR, which took place in December 2025. Leonard Mazur, the Chairman and CEO, highlighted that the initial market response has been overwhelmingly positive, with gross margins approximating 80% in the early months of sales.

In the quarter ending March 31, 2026, the company generated $1.7 million in product revenues, marking a significant milestone compared to the same period last year when revenue was nonexistent. This growth signals a successful initial order cycle from distributors and a promising trajectory as institutional demand for LYMPHIR begins to rise. Notably, 83% of targeted accounts have already included LYMPHIR in their formularies, reflecting the product's acceptance amongst key medical centers.

Strategic Financial Moves

Citius has secured up to $36.5 million in debt and equity financing, which is expected to bolster the company's commercial operations and allow for a complete rollout of its sales force by mid-summer 2026. The funds will support increased marketing efforts and facilitate the transition from an initial channel fill to sustained demand generation. With these arrangements, the company's financial stability appears to be enhancing, bolstered by a robust cash and cash equivalents balance of $2.6 million as of March 31, 2026.

International Expansion and Clinical Trials

Beyond domestic achievements, Citius Oncology has already initiated its first shipments of LYMPHIR to Europe, part of a broader strategy to penetrate international markets under existing distribution agreements. This expansion has potential implications for LYMPHIR's long-term value as it is set to be available across 19 different international markets, including parts of Southern Europe and the Middle East.

In addition, the company is supporting clinical evidence generation for LYMPHIR through investigational studies that reinforce its value in combination therapy settings. Recent preliminary results from Phase 1 studies have shown promise for LYMPHIR in conjunction with other treatments, including KEYTRUDA® for gynecologic cancers.

Future Outlook

Citius Oncology remains focused on maintaining a solid commercial foundation as it capitalizes on the strong market access that has been established. The leadership is optimistic about LYMPHIR's growth and aims to navigate the challenges of competitive treatment landscapes while continuously working to secure payer coverage and enhance patient access. With a dedicated field force and a comprehensive AI-powered machine learning platform aimed at engaging healthcare professionals, Citius Oncology is poised for strategic growth.

In summary, the financial results for Q2 2026, coupled with strategic moves toward expanding market access and improving clinical evidence, position Citius Oncology and LYMPHIR as significant players in the oncology therapeutic space. As LYMPHIR establishes itself in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), the company's broader goals include transforming LYMPHIR into a platform asset capable of combination therapies, which will further affirm its position in global markets.